Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
Open Access
- 15 October 1994
- journal article
- Published by American Society of Hematology in Blood
- Vol. 84 (8) , 2457-2466
- https://doi.org/10.1182/blood.v84.8.2457.2457
Abstract
The B-cell antigen CD20 is expressed on normal B cells and by nearly all B-cell lymphomas. This nonmodulating antigen provides an excellent target foKeywords
This publication has 0 references indexed in Scilit: